NCT02364206View on ClinicalTrials.gov

Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 8, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Adult Glioblastoma
Interventions
DRUG

LY2228820

DRUG

Temozolomide

RADIATION

radiotherapy

Trial Locations (6)

Unknown

CHU Amiens Sud-Salouel, Amiens

Institut Bergonié, Bordeaux

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Georges François Leclerc, Dijon

Centre Paul Strauss, Strasbourg

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

ARC Foundation for Cancer Research

OTHER

lead

Centre Jean Perrin

OTHER